Capital Increase Take-off for Natraceutical: Euro20 Million


Madrid - The Board of Spanish specialist for food, Natraceutical, approved in its April meeting the issue of 38,521,165 new shares, for a nominal amount of Euro3,852,116.5, allowing it to raise Euro20,031,005.80. The new shares will have the same rights as all bonds currently in circulation, taking effect from January 1, 2004, and with an issue price of Euro0.52.
Upon the approval of the prospectus by the Comisión Nacional de Mercado de Valores CNMV (National Stock Exchange Comission) , a 10-day period will be established to enable Natraceutical's shareholders to subscribe 5 new shares for every 19 old shares in their possession the day before this preferential subscription period commences and in which the rights, valued according to closing on April 22 at Euro0.075, will also be listed.
The Euro20 million , which Natraceutical will raise, will enable it to strengthen its resources and deal with projects which are included in the prospectus of its floating on the stock market, in addition to other product or business lines in which it's working.
Natraceutical currently markets 22 functional ingredients for the food industry. During 2003 and 2004 it has applied for five patents for functional ingredients and active principles, all derived from raw, natural materials, especially from the Mediterranean area. The company produces active compunds and biotechnological ingredients and develops functional foods as well. It also takes part in Biópolis, a biotechnological company directed at custom-made R&D activities for the food and pharmaceutical sectors, which was launched in April 2003 with the Consejo Superior de Investigaciones Científicas (Board of Scientific Research-CSIC), CAPSA and the Capital-Risk entity, TALDE. In 2003, Natraceutical achieved net profits of Euro2 million, thus multiplying six-fold its previous year's profits.
The world market for functional ingredients and nutraceuticals, whose main markets are the United States and Japan, rose to more than $34 billion in 2002, reflecting a growth of 9.2% compared with the previous year.



Granada-based Integromics S.L. has teamed up with the Galician Foundation of Genomic Medicine (FPGMX) in Santiago de Compostela to secure a €1m EU grant from the European Regional Development Fund and the Spanish government. With...



Oryzon Genomics S.A (Barcelona) is entering preclinical testing with a first-in-class bispecific LSD1/MAO-B inhibitor. In addition to the classic target MAO-B, the drug also blocks histone demethylase LSD1, an epigenetic histone...



Granada-based nLife Therapeutics S.L. has raised €5m in total from two venture capitalists. Through Caixa Capital Risc and Caixa Capital Biomed, La Caixa invested €2.5m. The same amount has been placed by Invercaria via its...



Ordesa Laboratories has filed a patent for a novel Bifidobacterium strain isolated from infant feces. It has the capacity to combat rotavirus, says a study (Appl. Environ. Microbiol., doi:10.1128/AEM.05548).



Madrid – Researchers from Spain and the US have discovered an Ebola-like filovirus in bats in northern Spain. The first known filovirus native to Europe was reported in a study published in the journal PLOS Pathogens...



Barcelona - South western Europe gets a new R&D unit in the field of biomolecules. Kymos Pharma, a contract researcher based in Barcelona, has signed an agreement with the French biotechnology group Ipsen to create a R&D group...



Barcelona/Saffron Walden – Almirall S.A. and BioFocus announced that they have entered into a collaboration agreement to identify new compounds against key targets in projects aimed at the treatment of respiratory and...



Madrid/Abu Dhabi – Spanish biotechs are seeking collaborations with firms in the United Arab Emirates. At the end of November, Grupo Zeltia and 14 other Spanish companies presented their research at the forum “Innovation,...



Madrid – The Spanish Minister of Innovation and Science Cristina Garmendia has responded to reports about Roche’s­ delivery stop in Greece and pessimistic expectations for Spain. In Sept­ember, she stressed that the atmosphere...

Displaying results 1 to 10 out of 181

1-10 Next >

© 2007-2015 BIOCOM


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week



All Events


Frankfurt am Main (DE)


Stock list

All quotes


  • BASILEA133.60 CHF4.70%
  • WILEX4.20 EUR3.45%


  • MEDIGENE8.58 EUR-4.88%
  • PAION2.51 EUR-4.56%
  • CYTOS0.63 CHF-3.08%


  • 4SC4.65 EUR257.7%
  • SYNGENTA422.00 CHF28.3%
  • SARTORIUS169.65 EUR18.6%


  • CYTOS0.63 CHF-37.6%
  • MEDIGENE8.58 EUR-33.2%
  • CO.DON2.89 EUR-8.3%


  • WILEX4.20 EUR418.5%
  • FORMYCON27.70 EUR316.5%
  • 4SC4.65 EUR315.2%


  • MOLOGEN4.92 EUR-53.7%
  • BIOFRONTERA2.30 EUR-28.6%
  • PAION2.51 EUR-22.8%

No liability assumed, Date: 25.05.2015

Current issue

All issues